Benign Prostatic Hyperplasia Market Analysis, Leading Companies, Emerging Drugs and Epidemiology Forecast

August 08 03:24 2020
Benign Prostatic Hyperplasia Market Analysis, Leading Companies, Emerging Drugs and Epidemiology Forecast

Delveinsight Business Research
DelveInsight’s “Benign Prostatic Hyperplasia Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the Benign Prostatic Hyperplasia, historical and forecasted epidemiology as well as the Benign Prostatic Hyperplasia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

As per the National Institute of Diabetes and Digestive and Kidney Diseases, benign prostatic hyperplasia (BPH) is a noncancerous condition in men in which the prostate gland is enlarged. BPH is also called benign prostatic hypertrophy or benign prostatic obstruction. The prostate goes through two main growth periods as a man ages. The first occurs early in puberty when the prostate doubles in size. The second phase of growth begins around age 25 and continues during most of a man’s life. BPH often occurs with the second growth phase.

The enlarged prostate gland presses against and pinches the urethra. The bladder wall becomes thicker. Ultimately the bladder may weaken and lose the ability to empty completely. The narrowing of the urethra and urinary retention causes many of the problems associated with BPH.

The diagnosis of BPH can be made by examining personal or family history, physical examination and medical tests. The American Urological Association (AUA) has built a BPH Symptom Score Index. It’s a series of questions about how often urinary symptoms happen. The score rates BPH from mild to severe.

 

Get FREE sample copy at: 

https://www.delveinsight.com/sample-request/benign-prostatic-hyperplasia-bph-market

 

benign-prostatic-hyperplasia-bph-market-size-and-share-analysis

The Benign Prostatic Hyperplasia market report also covers emerging drugs, current treatment practices, Benign Prostatic Hyperplasia market share of the individual therapies, current and forecasted Benign Prostatic Hyperplasia Market Size from 2017 to 2030 segmented by seven major markets.

The report provides a detailed current Benign Prostatic Hyperplasia treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market. 

 

Benign Prostatic Hyperplasia Market Key Facts

As per Boyle et al., half of the men over 60 may have symptoms compatible with BPH, and that up to 60% of men over 60 may have hypertension.

Benign prostatic hyperplasia is the most common prostate problem for men older than age 50. In 2010, as many as 14 million men in the United States had lower urinary tract symptoms suggestive of benign prostatic hyperplasia (NIDDK).

 

Key Benefits of Benign Prostatic Hyperplasia Market Report

  • Benign Prostatic Hyperplasia market report provides an in-depth analysis of Benign Prostatic Hyperplasia Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.

  • The Benign Prostatic Hyperplasia market report will help in developing business strategies by understanding the Benign Prostatic Hyperplasia Market trends & developments, key players and future market competition that will shape and drive the Benign Prostatic Hyperplasia market in the upcoming years.

  • The Benign Prostatic Hyperplasia market report covers Benign Prostatic Hyperplasia current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.

  • The report provides a detailed assessment of the Benign Prostatic Hyperplasia market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population,  comparative analysis of pipeline products with detailed clinical profiles, and other factors. 

 

Benign Prostatic Hyperplasia Market

The treatment of BPH includes watchful waiting, medical therapies, minimally invasive surgery, and surgery. Watchful waiting is the recommended strategy for patients with BPH who have mild symptoms and for those with moderate-to-severe symptoms who are not bothered by their symptoms and are not experiencing complications of BPH. Medical therapies for the treatment of BPH include alpha-blockers, phosphodiesterase-5 inhibitors, 5-alpha reductase inhibitors, and combination medications.

The key driver for the BPH market is an increase in the cases of risk factors such as obesity, heart and circulatory disease, type 2 diabetes, and a rise in the geriatric population. These factors, along with the expected launch of emerging therapies, will boost the BPH market in the forecast period.

The Benign Prostatic Hyperplasia market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Benign Prostatic Hyperplasia market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology. 

The report gives a thorough detail of Benign Prostatic Hyperplasia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders. 

 

Benign Prostatic Hyperplasia Epidemiology

The Benign Prostatic Hyperplasia epidemiology section covers insights about historical and current Benign Prostatic Hyperplasia patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

 

Benign Prostatic Hyperplasia Drugs Uptake and Key Market Players

The Benign Prostatic Hyperplasia Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Benign Prostatic Hyperplasia market or expected to get launched in the market during the study period. The analysis covers Benign Prostatic Hyperplasia market uptake by drugs; patient uptake by therapies; and sales of each drug.    

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Companies across the globe are diligently working toward the development of novel treatment therapies for Benign Prostatic Hyperplasia with a considerable amount of success over the years. Some of the key players in the Benign Prostatic Hyperplasia market includes:
GemVax & KAEL
Pfizer
Abbott Laboratories
Urovant Sciences
Ausio Pharmaceuticals
And many others

Drugs Covered
GV1001
Vibegron
AUS-131 (S-equo)
And many others.

 

Table of Content

1. Key Insights

2. Executive Summary 

3. Benign Prostatic Hyperplasia Competitive Intelligence Analysis

4. Benign Prostatic Hyperplasia Market Overview at a Glance

5. Benign Prostatic Hyperplasia Disease Background and Overview

6. Benign Prostatic Hyperplasia Patient Journey

7. Benign Prostatic Hyperplasia Epidemiology and Patient Population

8. Benign Prostatic Hyperplasia Treatment Algorithm, Current Treatment, and Medical Practices

9. Benign Prostatic Hyperplasia Unmet Needs

10. Key Endpoints of Benign Prostatic Hyperplasia Treatment

11. Benign Prostatic Hyperplasia Marketed Products

12. Benign Prostatic Hyperplasia Emerging Therapies

13. Benign Prostatic Hyperplasia Seven Major Market Analysis

14. Attribute Analysis

15. Benign Prostatic Hyperplasia Market Outlook (7 major markets)

16. Benign Prostatic Hyperplasia Access and Reimbursement Overview

17. KOL Views on the Benign Prostatic Hyperplasia Market.

18. Benign Prostatic Hyperplasia Market Drivers

19. Benign Prostatic Hyperplasia Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

 

Related Reports

Benign prostatic hyperplasia (BPH) Epidemiology Forecast to 2030

DelveInsight’s Benign prostatic hyperplasia (BPH) – Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Benign prostatic hyperplasia (BPH) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

 

Benign prostatic hyperplasia (BPH) Pipeline Insights, 2020

Benign prostatic hyperplasia (BPH) Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Benign prostatic hyperplasia (BPH) market.

 

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

view more articles

About Article Author